IQM-QUANTUM-COMPUTERS
12.11.2021 11:02:06 CET | Business Wire | Press release
As part of its long-term growth strategy, IQM Quantum Computers announces the operation of its new state-of-the-art fabrication and cryogenic characterization facility, which will expand its quantum processor production capacity. This new facility is situated close to its headquarters and quantum labs in Espoo, Finland and marks the company’s largest investment to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211112005477/en/
Today, IQM has started its pilot line and will expand with further fabrication lines in the future. These facilities will substantially accelerate the company’s quantum processor design cycle and increase its microelectronics fabrication capacity to keep pace with the dramatic technology shifts underway within national quantum programs, high-performance computing centers, and increasing demand from the industrial customers. In addition, the facilities will ensure the highest industry-level quality required for quantum computing.
“We continue to see increasing demand for our on-premises quantum computers across Europe and globally. Today, we are announcing our largest-ever investment in production to dramatically increase our quantum processor supply and build quantum computers of the future,” said Dr. Jan Goetz, CEO and co-founder of IQM Quantum Computers.
“This investment in equipment, infrastructure and our workforce increases our fabrication, new material research, 3D integration and product delivery capabilities. Today, we’ve started the first phase of our fabrication facility and we plan to continuously learn, and invest in further expansion.”
The pilot line at this facility will be ramped-up over the coming months, and it is expected to reach maximum production capacity during 2022.
This new facility will create high-tech job opportunities and serve as an advanced manufacturing workforce-development initiative. IQM plans to partner with the Finnish and European ecosystems and prepare its workforce for the long-term, high-quality employment and growth opportunities the new facilities will present.
This is another strategic step to strengthen IQM’s position as the category leader for on-premises quantum computers in Europe and provides a strong competitive advantage over other quantum startups.
Facts:
- Location: Espoo, Finland
- Investment: € 20 Million
- Area: 560 m2
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to commercialize application-specific quantum processors by the German Ministry of Education and Research in February 2021.
IQM has raised €71 million from private and public funding and has offices in Espoo, Finland; Munich, Germany; and Bilbao, Spain.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
www.meetiqm.com
You can watch the complete recording of the launch event here: https://youtu.be/EUvAfl7a0Vs
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005477/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom